Meeting
2022 ASCO Annual Meeting
Progression and mortality post-immunotherapy discontinuation among patients with BRAFV600-mutant (BRAF+) metastatic melanoma.
Authors
Sunandana Chandra
Northwestern University Feinberg School of Medicine, Chicago, IL
Sunandana Chandra , Evan Thomas Hall , You-Li Ling , Jackson Tang , Rohan Shah , Thach-Giao Truong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 9531)
DOI
10.1200/JCO.2022.40.16_suppl.9531
Abstract #
9531
Poster Bd #
124
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Patient and treatment characteristics of emergency presentations due to immune-mediated toxicities.
First Author: Sharon Hyo-Eun Nahm
Poster
2024 ASCO Annual Meeting
Ipilimumab and nivolumab plus UV1, an anticancer vaccination against telomerase, in advanced melanoma.
First Author: Paul Lorigan
Poster
2023 ASCO Annual Meeting
Efficacy of adjuvant therapy in patients (pts) with AJCC v8 stage IIIA cutaneous melanoma.
First Author: Piyush Grover
Poster
2022 ASCO Annual Meeting
Encorafenib plus binimetinib in patients with locally advanced, unresectable, or metastatic BRAFV600-mutant melanoma: Updated data from the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
First Author: Erika Richtig